FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117809110> ?p ?o ?g. }

• W2117809110 endingPage "71" @default.
• W2117809110 startingPage "68" @default.
• W2117809110 abstract "Objectives To compare the efficacy of two different topical betamethasone treatment regimens with respect to outcome and untoward effects in boys with phimosis. Methods Boys with phimosis whose parents opted for medical management were treated with topical betamethasone (0.05%) and manual retraction. One author (J.S.P.) prescribed betamethasone twice daily (BID) for 30 days (60 doses), and the other author (L.S.P.) prescribed betamethasone thrice daily (TID) for 21 days (63 doses). All boys had severe phimosis (prepuce unretractable to evaluate meatus) before treatment. The degree of phimosis was graded 1 month after treatment as severe, moderate (prepuce retractable to less than 50% glanular exposure), or mild (penile adhesions). Chi-square analysis (P <0.05) was used to compare the two groups. Treatment failure was defined as persistent severe phimosis. Results A total of 200 consecutive patients from each treatment group were included. The median patient ages were similar between the groups (3.8 years BID, 4.4 years TID). One child had an untoward effect (candidal dermatitis, TID regimen). There was an 84.5% response rate (moderate to no phimosis) with the BID regimen and an 87% response rate with the TID regimen (P = nonsignificant). Two patients with severe phimosis before treatment were diagnosed with congenital urethral malformations (hypospadias and epispadias) after treatment. Conclusions The topical application of betamethasone is a highly efficacious, safe, and well-tolerated treatment of phimosis in this large series of boys. The 21-day TID and 30-day BID regimens in conjunction with manual retraction are equally efficacious and can be offered to parents requesting nonsurgical management of phimosis. Untoward effects are rare with either regimen. Important urethral anomalies can occasionally be revealed. To compare the efficacy of two different topical betamethasone treatment regimens with respect to outcome and untoward effects in boys with phimosis. Boys with phimosis whose parents opted for medical management were treated with topical betamethasone (0.05%) and manual retraction. One author (J.S.P.) prescribed betamethasone twice daily (BID) for 30 days (60 doses), and the other author (L.S.P.) prescribed betamethasone thrice daily (TID) for 21 days (63 doses). All boys had severe phimosis (prepuce unretractable to evaluate meatus) before treatment. The degree of phimosis was graded 1 month after treatment as severe, moderate (prepuce retractable to less than 50% glanular exposure), or mild (penile adhesions). Chi-square analysis (P <0.05) was used to compare the two groups. Treatment failure was defined as persistent severe phimosis. A total of 200 consecutive patients from each treatment group were included. The median patient ages were similar between the groups (3.8 years BID, 4.4 years TID). One child had an untoward effect (candidal dermatitis, TID regimen). There was an 84.5% response rate (moderate to no phimosis) with the BID regimen and an 87% response rate with the TID regimen (P = nonsignificant). Two patients with severe phimosis before treatment were diagnosed with congenital urethral malformations (hypospadias and epispadias) after treatment. The topical application of betamethasone is a highly efficacious, safe, and well-tolerated treatment of phimosis in this large series of boys. The 21-day TID and 30-day BID regimens in conjunction with manual retraction are equally efficacious and can be offered to parents requesting nonsurgical management of phimosis. Untoward effects are rare with either regimen. Important urethral anomalies can occasionally be revealed." @default.
• W2117809110 created "2016-06-24" @default.
• W2117809110 creator A5039579287 @default.
• W2117809110 creator A5054994233 @default.
• W2117809110 date "2008-07-01" @default.
• W2117809110 modified "2023-09-25" @default.
• W2117809110 title "The Efficacy of Topical Betamethasone for Treating Phimosis: A Comparison of Two Treatment Regimens" @default.
• W2117809110 cites W1645703214 @default.
• W2117809110 cites W1975877157 @default.
• W2117809110 cites W1980008409 @default.
• W2117809110 cites W2008582839 @default.
• W2117809110 cites W2084383279 @default.
• W2117809110 cites W2091671458 @default.
• W2117809110 cites W2110638598 @default.
• W2117809110 cites W2137325780 @default.
• W2117809110 cites W2161558884 @default.
• W2117809110 cites W2763039248 @default.
• W2117809110 cites W4321059164 @default.
• W2117809110 doi "https://doi.org/10.1016/j.urology.2008.02.030" @default.
• W2117809110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18455770" @default.
• W2117809110 hasPublicationYear "2008" @default.
• W2117809110 type Work @default.
• W2117809110 sameAs 2117809110 @default.
• W2117809110 citedByCount "31" @default.
• W2117809110 countsByYear W21178091102012 @default.
• W2117809110 countsByYear W21178091102013 @default.
• W2117809110 countsByYear W21178091102014 @default.
• W2117809110 countsByYear W21178091102017 @default.
• W2117809110 countsByYear W21178091102018 @default.
• W2117809110 countsByYear W21178091102019 @default.
• W2117809110 countsByYear W21178091102020 @default.
• W2117809110 countsByYear W21178091102021 @default.
• W2117809110 countsByYear W21178091102022 @default.
• W2117809110 countsByYear W21178091102023 @default.
• W2117809110 crossrefType "journal-article" @default.
• W2117809110 hasAuthorship W2117809110A5039579287 @default.
• W2117809110 hasAuthorship W2117809110A5054994233 @default.
• W2117809110 hasConcept C126322002 @default.
• W2117809110 hasConcept C141071460 @default.
• W2117809110 hasConcept C2777493422 @default.
• W2117809110 hasConcept C2777990738 @default.
• W2117809110 hasConcept C2779176196 @default.
• W2117809110 hasConcept C2781162121 @default.
• W2117809110 hasConcept C2781413609 @default.
• W2117809110 hasConcept C71924100 @default.
• W2117809110 hasConceptScore W2117809110C126322002 @default.
• W2117809110 hasConceptScore W2117809110C141071460 @default.
• W2117809110 hasConceptScore W2117809110C2777493422 @default.
• W2117809110 hasConceptScore W2117809110C2777990738 @default.
• W2117809110 hasConceptScore W2117809110C2779176196 @default.
• W2117809110 hasConceptScore W2117809110C2781162121 @default.
• W2117809110 hasConceptScore W2117809110C2781413609 @default.
• W2117809110 hasConceptScore W2117809110C71924100 @default.
• W2117809110 hasIssue "1" @default.
• W2117809110 hasLocation W21178091101 @default.
• W2117809110 hasLocation W21178091102 @default.
• W2117809110 hasOpenAccess W2117809110 @default.
• W2117809110 hasPrimaryLocation W21178091101 @default.
• W2117809110 hasRelatedWork W2015072280 @default.
• W2117809110 hasRelatedWork W2017998898 @default.
• W2117809110 hasRelatedWork W2032962420 @default.
• W2117809110 hasRelatedWork W2058379080 @default.
• W2117809110 hasRelatedWork W2117809110 @default.
• W2117809110 hasRelatedWork W2125491527 @default.
• W2117809110 hasRelatedWork W2166856352 @default.
• W2117809110 hasRelatedWork W2189487456 @default.
• W2117809110 hasRelatedWork W2396856927 @default.
• W2117809110 hasRelatedWork W3139878215 @default.
• W2117809110 hasVolume "72" @default.
• W2117809110 isParatext "false" @default.
• W2117809110 isRetracted "false" @default.
• W2117809110 magId "2117809110" @default.
• W2117809110 workType "article" @default.